← Back to Search

Antibiotic

DFD-29 for Rosacea

Phase 1

Waitlist Available

Research Sponsored by Journey Medical Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to week 16

Awards & highlights

Study Summary

This trial tests a medication to see if it can improve skin, gut, and vaginal health.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to week 16

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to week 16

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Superinfection

Changes in the number of colony forming units (CFUs) of microbial species.

Side effects data

From 2017 Phase 2 trial • 22 Patients • NCT01746043

20%

Peripheral Neuropathy

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

Armodafinil+Minocycline

Minocycline

Armodafinil

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: DFD-29Experimental Treatment1 Intervention

DFD-29 (minocycline hydrochloride) capsules, 40 mg will be administered orally once daily for 16 weeks.

Group II: PlaceboPlacebo Group1 Intervention

Placebo capsules will be administered orally once daily for 16 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Minocycline hydrochloride capsules

2022

Completed Phase 1

~60

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Dr. Reddy's Laboratories LimitedIndustry Sponsor

234 Previous Clinical Trials

23,169 Total Patients Enrolled

5 Trials studying Rosacea

925 Patients Enrolled for Rosacea

Journey Medical CorporationLead Sponsor

9 Previous Clinical Trials

2,313 Total Patients Enrolled

2 Trials studying Rosacea

653 Patients Enrolled for Rosacea

Srinivas Sidgiddi, M.D.Study DirectorJourney Medical Corporation

1 Previous Clinical Trials

550 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this medical trial open to those of legal age?

"According to the set requirements, this study is only accessible for individuals aged 18-65. Those below 18 years old and above 65 have 1 trial and 12 trials respectively that they can enrol into."

Answered by AI

Is this experiment actively seeking participants?

"According to clinicaltrials.gov, this experiment is no longer recruiting participants; although it was initially posted on September 30th 2022 and updated November 7th 2022 the trial has been closed for enrollment. Fortunately, 12 other trials are currently seeking patients in related fields of research."

Answered by AI

What safeguards have been put in place to ensure the safety of those taking DFD-29?

"As DFD-29 is currently in Phase 1 trials, there is limited evidence for its safety and efficacy; our team at Power determined the riskiness of this medication to be a score of 1."

Answered by AI

May I participate in the experiment?

"To be accepted into this trial, potential participants must possess a diagnosis of rosacea and fall within the age range from 18 to 65. The study is due to recruit up to 60 individuals."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

2022. "Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05597462.